Efficacy and safety of sintilimab plus albumin-bound-paclitaxel in recurrent or metastatic cervical cancer: a multicenter, open-label, single-arm, phase II trial
-
Published:2023-11
Issue:
Volume:65
Page:102274
-
ISSN:2589-5370
-
Container-title:eClinicalMedicine
-
language:en
-
Short-container-title:eClinicalMedicine
Author:
Wang Yin,
Zhao Jing,
Liang HaixiORCID,
Liu Junxiu,
Huang Shenjiao,
Zou Guorong,
Huang Xin,
Lan Chunyan
Reference17 articles.
1. A review of cervical cancer: incidence and disparities;Buskwofie;J Natl Med Assoc,2020
2. Prevention, screening, treatment and follow-up of gynecological cancers: state of art and future perspectives;Golia;Clin Exp Obstet Gynecol,2023
3. Improved survival with bevacizumab in advanced cervical cancer;Tewari;New Engl J Med,2014
4. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study;Moore;J Clin Oncol,2004
5. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer;Colombo;New Engl J Med,2021
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献